GPCR
New data, same brutal weight-loss race
Structure Therapeutics came out swinging with more clinical data on two oral candidates, ACCG-2671 and aleniglipron, and the message was pretty simple: the pills are doing pill things. They’re lowering weight, they’re showing tolerability, and they’re giving investors another peek at whether this company can muscle into the GLP-1 club without needing a weekly needle.
ACCG-2671: tiny study, decent vibes
In an early Phase 1/2a study, 31 healthy, non-obese participants took ACCG-2671 across doses from 1 mg to 10 mg. The headline stat: a single 10 mg dose led to a 3.3% mean body weight reduction by Day 24. That’s not a home run by itself, but in early obesity-land, it’s enough to keep the lights on and the scientists nodding.
The drug also posted a terminal half-life of about six days, which matters because it helps answer the “how often do I need to take this thing?” question. On top of that, the trial saw no serious adverse events or liver enzyme elevations, though the usual GI gremlins showed up at higher doses.
Aleniglipron: the marathon runner
The ACCESS extension study gave aleniglipron a much longer runway, and the data looked sturdier. Patients on the top 180 mg dose saw as much as 16.2% body weight loss through 72 weeks, with no obvious plateau. Starting at 2.5 mg seemed to help with stomach side effects, and fewer than 5% of participants quit because of adverse events.
That’s the kind of profile a weight-loss company wants to brag about at dinner, because tolerability is half the battle. Efficacy is great, but if people feel like they got into a bar fight with their digestive system, they’re out.
What investors should watch next
Structure also said it’s moving the program forward, with a Phase 3 ACCOMPLISH study already underway and three more trial readouts expected in the fourth quarter of 2026. The real question now is whether these results are strong enough to make oral obesity drugs feel less like a science project and more like a business.
Big picture: the science is encouraging, but the market for weight-loss drugs is basically a crowded subway at rush hour. Good data helps — a lot — but investors are still waiting for proof that Structure can turn promising pills into a real commercial lane.